Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials

Brunt, Elizabeth M., Kleiner, David E., Wilson, Laura A., Sanyal, Arun J., Neuschwander‐Tetri, Brent A., for the Nonalcoholic Steatohepatitis Clinical Research Network·2019·Hepatology
DOI 10.1002/hep.30418

Cited by (155)

Items 101–155 of 155

  1. Fatty Liver Disease
    DINA G. TINIAKOS, Quentin Mark Anstee, Elizabeth M. Brunt, Alastair D. Burt · 2023 · Elsevier eBooks
  2. Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease
    Mattias Mandorfer, Georg Semmler, Elmar Stephan Aigner, Alexander Bräuer, Johanna Maria Brix, Martin Clodi, Christian Datz, Maria Effenberger, Daniel Moritz Felsenreich, Bernhard H. Ludvik et al. · 2025 · Wiener klinische Wochenschrift
  3. Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis
    Rafael dos Santos Borges, Eliabe Silva de Abreu, Giovanni Gosch Berton, Luiza Haikal de Paula, Ana Flávia Conegundes, Jefferson Manoel Borges Martins, Marcelo Albuquerque Barbosa Martins, Aladdin Dahbour, Matheus Vanzin Fernandes, Manal F. Abdelmalek · 2025 · JHEP Reports
  4. The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies
    Elliot B. Tapper, Charlotte Fleming, Adriana Rendon, João Diogo da Rocha Fernandes, Pierre Johansen, Margarida Augusto, Sunita Nair · 2022 · Gastro Hep Advances
  5. Paediatric non-alcoholic fatty liver disease: an approach to pathological evaluation
    Chiyun Wang, Anita K. Pai, Juan Putra · 2022 · Journal of Clinical Pathology
  6. Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints
    Elias Laurin Meyer, Peter G Mesenbrink, Nicholas A. Di Prospero, Juan Manuel Pericàs, Ekkehard Glimm, Vlad Ratziu, Elena Sena, Franz König, on behalf of the EU-PEARL NASH Investigators · 2023 · PLoS ONE
  7. Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial
    Rohit Seth Loomba, Jacob George, Laurent Castéra, Sven Francque, Eric Lawitz, Ahsan Shoeb, Jesper O. Clausen, Birgitte Andersen, Anna Bille Larsen, Lise Lotte Gluud · 2026 · The Lancet. Gastroenterology & hepatology
  8. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints
    Albert Do, Ysabel C. Ilagan‐Ying, Wajahat Zafar Mehal, Joseph K. Lim · 2020 · Expert Opinion on Drug Discovery
  9. Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis
    James Phillip Esteban, Amon Asgharpour · 2020 · Gastroenterology Clinics of North America
  10. Identification of Key Biomarkers and Immune Infiltration in Liver Tissue after Bariatric Surgery
    Xiaoyan Zhang, Jingxin Li, Tiancai Liu, Min Zhao, Baozhu Liang, Hong Chen, Zhen Zhang · 2022 · Disease Markers · Retracted
  11. Problems and Challenges Associated with Renaming Non-alcoholic Fatty Liver Disease to Metabolic Associated Fatty Liver Disease
    Minghui Zeng, Lin Chen, Yuqin Li, Yuqiang Mi, Liang Xu · 2023 · Infectious Diseases & Immunity
  12. Altered Inflammatory Pathway but Unaffected Liver Fibrosis in Mouse Models of Nonalcoholic Steatohepatitis Involving Interleukin-1 Receptor-Associated Kinase 1 Knockout
    Ying Lei, Tianxiao Yang, Aijing Shan, Di Wei, Mengyao Dai, Jingminjie Nan, Dongxue Liu, Yanan Cao, Xiuli Jiang · 2020 · Medical Science Monitor
  13. Accuracy of Velacur in Assessing MASLD and MASH Patients Using Biopsy as the Gold Standard
    Muhammad Y. Sheikh, Nameer Hasan, Marwan Almozuaghi, Nadeem M. Akhtar, Yugjeet Grewal, Caitlin Schneider · 2025 · Diagnostics
  14. Green jackfruit flour ameliorates MASH and development of HCC via the AMPK and MAPK signaling pathways in experimental model systems
    Diwakar Suresh, Bharathwaaj Gunaseelan, Akshatha N. Srinivas, Amith Bharadwaj, James Joseph, Megha Megha, Thomas Varughese, Suchitha Satish, Deepak Suvarna, Prasanna K. Santhekadur et al. · 2025 · Scientific Reports
  15. Traitements pharmacologiques de la NASH
    Lawrence Serfaty · 2019 · La Presse Médicale
  16. The nomenclature of fatty liver disease and its impact on obesity traits, insulin resistance, and hepatic fibrosis
    Liangguang Xiang, Xiaoyun Li, Jiamin Gong, Long He, Wanxin Li, Jun Chen, Ruimei Feng, Shanshan Du, Weimin Ye · 2025 · Lipids in Health and Disease
  17. Quantitative assessment of inflammation and evaluation of spatial heterogeneity for non-alcoholic fatty liver disease in mice based on iron-adjustive T1
    Lujie Li, Bing Liao, Huasong Cai, Yinhong Zhang, Kan Deng, Yuying Chen, Meicheng Chen, Xiaoqi Zhou, Mimi Tang, Zhi Dong et al. · 2023 · Quantitative Imaging in Medicine and Surgery
  18. Clinical associations of portal-based disease in MASLD: proposal of a new histological scoring system
    Daniela S. Allende, Cynthia D. Guy, David Erwin Kleiner, Danielle H. Carpenter, Ryan M. Gill, Oscar W. Cummings, Melissa J. Contos, Matthew M. Yeh, Patricia H. Belt, Laura Wilson et al. · 2025 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  19. Two‐Step Machine Learning Model Enhances Identification of High‐Risk Metabolic Dysfunction‐Associated Steatotic Liver Disease
    Zheng'ao Xu, Yongfen Zhu, Fengjuan Chen, Qiong-Yue Fan, Ruiqi Wang, Yilong Fu, Xunxun Wu, Li Zhu, Fushuang Ha, Qing Ye et al. · 2025 · Liver International
  20. Management of obesity in advanced chronic liver disease
    Cyrielle Caussy, Sven Francque · 2026 · JHEP Reports
  21. Pharmacology of NASH
    Somaya A. M. Albhaisi, Arun Jayant Sanyal · 2021 · Elsevier eBooks
  22. ASSOCIATION OF LOW GFR AND NON-ALCOHOLIC HEPATOSTEATOSIS ON FIBROSCAN OF LIVER
    Khurram Baqai, Mahvesh Mahmud, Maryam Anwar, Shoukat Ali Samejo, Nida Hussain, Ambreen Wasim · 2023 · Journal of Ayub Medical College Abbottabad
  23. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: diagnostic and therapeutic aspects. Review
    T. М. Bentsa · 2023 · Modern Gastroenterology
  24. Weight loss treatment for COVID-19 in patients with NCDs: a pilot prospective clinical trial
    Kuat Oshakbayev, Aigul Durmanova, Zulfiya Meirkhanovna Zhankalova, Alisher Idrisov, Gulnara Bedelbayeva, Meruyert Gazaliyeva, Altay Nabiyev, Attila Tordai, Bibazhar Abayevna Dukenbayeva · 2024 · Scientific Reports
  25. A Model-Based Evaluation of Noninvasive Biomarkers to Reflect Histological Nonalcoholic Fatty Liver Disease Scores
    Iris K. Minichmayr, Elodie L. Plan, Benjamin Weber, Sebastian Ueckert · 2024 · Pharmaceutical Research
  26. Semaglutide and MASH resolution: A pooled analysis of recent trials
    Alaa Abdrabou Abouelmagd, Ahmed Elazab, Mohamed Diaa Gabra, Hazem Maarouf Abosheaishaa · 2025 · Diabetes Obesity and Metabolism
  27. Biochemical Biomarkers of NAFLD/NASH
    Ciro Celsa, Grazia Pennisi, Federica Spatola, Aurora Giannetti, Salvatore Petta · 2020 · Springer eBooks
  28. Analytical and Clinical Validation of AIM-NASH: A Digital Pathology Tool for Artificial Intelligence-based Measurement of Nonalcoholic Steatohepatitis Histology
    Hanna Pulaski, Stephen A. Harrison, Shraddha S. Mehta, Arun Jayant Sanyal, Marlena C. Vitali, Laryssa C. Manigat, Hypatia Hou, Susan P. Madasu Christudoss, Sara M. Hoffman, Adam Stanford-Moore et al. · 2024 · medRxiv
  29. Head to head: should portal inflammation be part of grading necroinflammatory activity in metabolic dysfunction‐associated steatotic liver disease?
    Daniela Allende, Alastair D. Burt · 2026 · Histopathology
  30. Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
    Dmitry Victorovich Garbuzenko · 2022 · Russian Journal of Gastroenterology Hepatology Coloproctology
  31. Steatosis, Steatohepatitis and Related Conditions
    Jay H. Lefkowitch · 2020 · Elsevier eBooks
  32. Azonal steatosis correlates with disease severity and poor outcome of nonalcoholic fatty liver disease
    Xiao Fei Tong, Xinyan Zhao, Ya Meng Sun, Yi Wen Shi, Min� Li, Xiao Ning Wu, Jing Jie Zhao, Li Ling Yang, Zheng Zhao Lu, Xiaojuan Ou et al. · 2023 · Journal of Digestive Diseases
  33. Perspectives of Drug Therapy for Non-Alcoholic Steatohepatitis-Related Liver Fibrosis
    Dmitry Victorovich Garbuzenko · 2025 · Fibrosis
  34. Is the grade of ballooned hepatocytes a significant risk factor for rapid progression of hepatic fibrosis in patients with NAFLD?
    for the Japan Study Group of Non-Alcoholic Fatty Liver Disease (JSG-NAFLD), Yoshio Sumida, Masashi Yoneda, Takeshi Okanoue · 2019 · Journal of Gastroenterology
  35. AATF-mediated Liver Damage and Inflammation to Cancer: Therapeutic Intervention by Curcumin in Experimental MASH-HCC
    Akshatha N. Srinivas, Diwakar Suresh, Saravana Babu Chidambaram, Prasanna K. Santhekadur, Divya P. Kumar · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  36. Mitochondrial role in NAFLD as a chronic disease
    Nicolás Salva-Pastor, Mayra Domínguez‐Pérez, Norberto Carlos Chávez-Tapia, Natalia Nuño‐Lámbarri · 2020 · Elsevier eBooks
  37. Berberine Depresses Hepatocellular Lipogenesis Via Targeting to Methyltransferase SETD2
    Dai Li, Shuang Lü, Tianbai Shen, Jianjie Chen, Ying Li · 2022 · SSRN Electronic Journal
  38. Weight loss in patients with COVID-19 and Influenza in comorbidity with NCDs: a pilot prospective clinical trial
    Kuat Oshakbayev, Aigul Durmanova, Alisher Idrisov, Zulfiya Meirkhanovna Zhankalova, Gulnara Bedelbayeva, Meruyert Gazaliyeva, Attila Tordai, Altay Nabiyev, Bibazhar Abayevna Dukenbayeva · 2022 · medRxiv
  39. Weight loss treatment of COVID-19 in patients with NCDs: a pilot prospective clinical trial
    Kuat Oshakbayev, Aigul Durmanova, Zulfiya Meirkhanovna Zhankalova, Alisher Idrisov, Gulnara Bedelbayeva, Meruyert Gazaliyeva, Altay Nabiyev, Attila Tordai, Bibazhar Abayevna Dukenbayeva · 2023 · Research Square
  40. Non-alcoholic fatty liver disease: from understanding risk factors to finding optimal treatment regimens: A review
    Daria A. Teplyuk, Aliya A. Kaisina, Shabnam I. Ibragimova, Afina Bestavashvili, Ирина Олеговна Тинькова, E.Yu. Pashkova, Jamilya A. Kaibullayeva, Nersesov Alexander Vitalevich, Chavdar S Pavlov · 2023 · Consilium Medicum
  41. Green Jackfruit Flour Prevents Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma via the AMPK and MAPK Signaling Pathways
    Diwakar Suresh, Bharathwaaj Gunaseelan, Akshatha N. Srinivas, Amith Bharadwaj, James Joseph, Megha Megha, Thomas Varghese, Suchitha Satish, Deepak Suvarna, Prasanna K. Santhekadur et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  42. Pharmacologic treatment of NAFLD/NASH and their related comorbidities
    Sun H. Kim, Paul Yien Kwo · 2024 · Elsevier eBooks
  43. Cirrhose métabolique : une entité en plein essor
    Vlad Ratziu · 2024 · Bulletin de l Académie Nationale de Médecine
  44. Histopathology of MASLD: Insights into Liver Tissue Changes
    Sven Francque, Ann L. C. Driessen · 2024 · Springer eBooks
  45. Prevention of HCC
    Ashraf Mohammad Al-Breedy, Mohamed Kamal Shaker, Medhat Elsahhar · 2025 · Springer eBooks
  46. Additional file 1 of CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease
    Kim, Ha Neul, Jeon, Hong Jae, Hei Gwon Choi, Kwon, In Sun, Rou, Woo Sun, Lee, Jeong Eun, Lee, Tae Hee, Kim, Seok Hyun, Lee, Byung Seok, Shin, Kyung Sook et al. · 2023 · Figshare
  47. Additional file 4 of CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease
    Kim, Ha Neul, Jeon, Hong Jae, Hei Gwon Choi, In Sun Kwon, Rou, Woo Sun, Lee, Jeong Eun, Lee, Tae Hee, Kim, Seok Hyun, Lee, Byung Seok, Shin, Kyung Sook et al. · 2023 · Figshare
  48. Additional file 2 of CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease
    Kim, Ha Neul, Jeon, Hong Jae, Hei Gwon Choi, Kwon, In Sun, Rou, Woo Sun, Lee, Jeong Eun, Lee, Tae Hee, Kim, Seok Hyun, Lee, Byung Seok, Shin, Kyung Sook et al. · 2023 · Figshare
  49. Additional file 3 of CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease
    Kim, Ha Neul, Jeon, Hong Jae, Hei Gwon Choi, In Sun Kwon, Rou, Woo Sun, Lee, Jeong Eun, Lee, Tae Hee, Kim, Seok Hyun, Lee, Byung Seok, Shin, Kyung Sook et al. · 2023 · Figshare
  50. Hepatic loss of AATF attenuates MASH by suppressing AKT–mTORC1 signaling and reprogramming lipid metabolism
    Akshatha N. Srinivas, Diwakar Suresh, Prajna Anirvan, Manju Moorthy, Gopalkrishna Ramaswamy, Suma Maduvanahalli Nataraj, Prasanna K. Santhekadur, Deepak Suvarna, Shivaram P. Singh, Divya P. Kumar · 2026 · Molecular Medicine
  51. Comparative efficacy of SGLT2 Inhibitors and Obeticholic Acid in MAFLD and Fibrosis: A Systematic Review
    Thenmozhi Ganesh, Vignesh subramani, Rajesh kannan.S, Yuvaraj.G · 2026 · Research Square
  52. The evolving landscape of pathologic interpretation in metabolic dysfunction-associated steatotic liver disease
    Daniela S. Allende · 2026 · Human Pathology
  53. Impact of Obeticholic Acid Therapy on Insulin Resistance and Metabolic Parameters in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)
    Majid Almansouri, Hani Shalabi, Mohammed Matoog Karami, Omar Alharthy, Ali Kabli, Mohammad Khalil, Maan S. Alkhattabi, Dahlia Soleman A. Mirdad, Ahmed Alharthy, Ahmed Haitham Abduljabbar et al. · 2026 · International Journal of Hepatology
  54. Non-invasive Assessment and Therapeutic Targeting in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Overcoming the Dissonance Between Drug Development and Precision Medicine
    Eleni Theocharidou, Konstantinos Arvanitakis, Theocharis Koufakis, Emmanuel A. Tsochatzis, Sven Francque, Georgios S. Germanidis · 2026 · Drugs
  55. BindingDB Entry 50014057: Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis.
    BindingDB · 2022 · UC San Diego